

PRESCRIBING INFORMATION: Indications: Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID associated duodenal ulcer, oesophageal reflux disease, severe oesophagitis, chronic episodic dyspepsia. **Dosage:** *Adults:* Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. Alternatively, in duodenal ulcers, 300mg in the morning and evening for four weeks to achieve optimal healing. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Prevention of NSAID associated duodenal ulcer: 150mg twice daily concomitantly with NSAID therapy. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Moderate to severe oesophagitis: 150mg four times daily for up to twelve weeks (see data sheet for full dosage instructions). *Children:* Oral dose for peptic ulcer: 2mg/kg to 4mg/kg, twice daily to a maximum of 300mg per day. **Contra-indications:** Patients with known hypersensitivity to ranitidine. **Precautions:** In patients in whom sodium restriction is indicated, care should be taken when administering sodium-containing Effervescent Tablets. Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients taking NSAIDs concomitantly with Zantac is recommended, especially if elderly. Reduce dosage in presence of severe renal failure (see data sheet). Like other drugs, use during pregnancy and lactation only if strictly necessary. **Side effects:** Headache, dizziness, skin rash, occasional hepatitis. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other H_2-receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **Presentations:** Zantac 150 Tablets each containing 150mg ranitidine HCl (Product licence number 0004/0279, 60 tablets £29·76); Zantac 300 Tablets each containing 300mg ranitidine HCl (Product licence number 0004/0302, 30 tablets £27·43); Zantac Dispersible Tablets each containing 150mg ranitidine HCl (Product licence number 0004/0298, 60 tablets £31·25); Zantac Effervescent Tablets each containing 150mg ranitidine HCl and 14·3mEq sodium (Product licence number 0004/0392, 60 tablets £31·25); Zantac Effervescent Tablets each containing 300mg ranitidine HCl and 20·8mEq sodium (Product licence number 0004/0393, 30 tablets £31·25); Zantac Syrup each 10ml dose containing 150mg ranitidine HCl (Product licence number 0004/0310, 300ml bottle £22·32). **Product licence holder:** Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. Zantac is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Tel: 081 990 9000.

Glaxo

Zantac
RANITIDINE HCl

AUDIT IN ACTION covers audit both in hospitals and in general practice. Valuable reading for all those concerned to improve the quality of health care.

UK £10.95; Abroad £13.00 (BMA members £9.95 or £12.00)

THE FUTURE OF GENERAL PRACTICE discusses topics at the heart of this debate including research, audit, list sizes, fund holding, and general practitioners' educational needs.

UK £7.95; Abroad £10.00 (BMA members £7.45 or £9.50)

THE HEALTH OF THE NATION—THE BMJ VIEW
Contributors discuss each of the 16 key areas defined in the government's strategy and suggest other subjects that might qualify as key areas.

UK £9.95; Abroad £12.00 (BMA members £8.95 or £11.00)

All these books are available from:
BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9JR, the BMJ Bookshop in BMA House and major medical booksellers.

American Express/Mastercard/VISA credit cards accepted (please give full details).



All prices include postage, by air abroad

THE QUALITIES OF LEADERSHIP

Experience

Unique among foam treatments, Colifoam has over 12 years of proven efficacy and safety in clinical practice.

Trust

Equally as effective as steroid enemas,[1,2] Colifoam is well documented and is the most prescribed topical treatment[3] for ulcerative colitis.

Confidence

Colifoam's simplicity and effectiveness has transformed the lives of thousands of patients, enabling them to pursue active social and working lives.[1]

COLIFOAM
10% Hydrocortisone acetate foam.

The leading topical treatment for ulcerative colitis.

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. References 1. Somerville KW et al. British Medical Journal 1985; 291:866. 2. Ruddell WSJ et al. Gut 1980; 21:885-889. 3. Independent Research Audit. Data on File. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Broadwater Road, Welwyn Garden City, Herts. AL7 3SP.

"Sorry to bring it up, but I need some Motilium"

If you are called on to deal with acute nausea and vomiting remember Motilium and avoid a flap. Clinical trials have shown Motilium to be more effective than metoclopramide[1,2] and unlikely to cause central side-effects[3,4,5] because it does not readily cross the blood-brain barrier.[6]

Motilium: it will be a feather in your cap.

Motilium®

domperidone

effective relief of acute nausea and vomiting — whatever the cause

Prescribing information Uses: *Adults (including elderly):* The acute treatment of nausea and vomiting of any aetiology, and for up to 12 weeks treatment of nausea and vomiting due to L-dopa and bromocriptine. Not recommended for chronic use nor, routinely, for prophylaxis of post-operative vomiting. *Children:* Only for nausea and vomiting following cancer chemotherapy or irradiation. **Presentation:** *Motilium tablets (domperidone 10mg):* Cartons of 30 and 100 tablets in blister strips of 10. Basic NHS cost 30 tablets: £2.52, 100 tablets: £8.42. PL0071/0287. *Motilium suspension (domperidone 1mg/ml):* Bottles of 200ml. Basic NHS cost of 200ml: £1.85. PL0071/0292. *Motilium suppositories (domperidone 30mg):* Cartons of 10 in blister strips of 5. Basic NHS cost 10 suppositories: £2.72. PL0071/0290. **Dosage:** Route, dose and frequency of dosaging should be adjusted according to severity and duration of symptoms. *Adults (including elderly):* Tablets or suspension: 10-20mg at 4-8 hourly intervals. Suppositories: 1 or 2 at 4-8 hourly intervals. *Children:* Suspension: 0.2-0.4mg/kg at 4-8 hourly intervals. Suppositories: for children aged 2-12 years, 1-4 daily according to body weight (see Data Sheet). **Contra-indications, Warnings, etc.:** No specific contra-indications. Safety of Motilium in pregnancy has not yet been established, therefore it should be avoided in those who are pregnant. **Side-effects:** In common with other dopamine antagonists Motilium produces a rise in serum prolactin which may be associated with galactorrhoea, and less frequently, gynaecomastia. Domperidone does not readily cross the normally functioning blood-brain barrier. However, acute extrapyramidal dystonic reactions have been reported with Motilium.

References: 1. Moriga M, *Roy. Soc. Med. Int. Cong. Symp. Ser.* 1981; **36**: 77-79. 2. De Loose F, *Pharmatherapeutica* 1979; **2** (3): 140-146. 3. Van Ganse W, *Curr. Ther. Res.* 1978; **23** (6): 695-701. 4. Van Outryve M *et al.*, *Postgrad. Med. J.* 1979; **55** (Suppl. 1): 33-35. 5. Van de Mierop L *et al.*, *Digestion* 1979; **19**: 244-250. 6. Laduron PM & Leysen JE, *Biochem. Pharmacol.* 1979; **28**: 2161-2165. Motilium is a registered trade mark. Further information available from: Sanofi Winthrop Limited, 1 Onslow Street, Guildford, Surrey GU1 4YS.

sanofi WINTHROP

PRESCRIBING INFORMATION: Indications: Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID associated duodenal ulcer, oesophageal reflux disease, severe oesophagitis, chronic episodic dyspepsia. **Dosage:** *Adults:* Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. Alternatively, in duodenal ulcers, 300mg in the morning and evening for four weeks to achieve optimal healing. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Prevention of NSAID associated duodenal ulcer: 150mg twice daily concomitantly with NSAID therapy. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Moderate to severe oesophagitis: 150mg four times daily for up to twelve weeks (see data sheet for full dosage instructions). *Children:* Oral dose for peptic ulcer: 2mg/kg to 4mg/kg, twice daily to a maximum of 300mg per day. **Contra-indications:** Patients with known hypersensitivity to ranitidine. **Precautions:** In patients in whom sodium restriction is indicated, care should be taken when administering sodium-containing Effervescent Tablets. Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients taking

Glaxo



NSAIDs concomitantly with Zantac is recommended, especially if elderly. Reduce dosage in presence of severe renal failure (see data sheet). Like other drugs, use during pregnancy and lactation only if strictly necessary. **Side effects:** Headache, dizziness, skin rash, occasional hepatitis. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other H_2-receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **Presentations:** Zantac 150 Tablets each containing 150mg ranitidine HCl (Product licence number 0004/0279, 60 tablets £29·76); Zantac 300 Tablets each containing 300mg ranitidine HCl (Product licence number 0004/0302, 30 tablets £27·43); Zantac Dispersible Tablets each containing 150mg ranitidine HCl (Product licence number 0004/0298, 60 tablets £31·25); Zantac Effervescent Tablets each containing 150mg ranitidine HCl and 14·3mEq sodium (Product licence number 0004/0392, 60 tablets £31·25); Zantac Effervescent Tablets each containing 300mg ranitidine HCl and 20·8mEq sodium (Product licence number 0004/0393, 30 tablets £31·25); Zantac Syrup each 10ml dose containing 150mg ranitidine HCl (Product licence number 0004/0310, 300ml bottle £22·32). **Product licence holder:** Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. Zantac is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Tel: 081 990 9000.

Zantac
RANITIDINE HCl

Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.

colofac®

mebeverine

loosens the grip of IBS

Prescribing Information
Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml: Basic NHS price £3.50. **Indications:** 1. Irritable bowel syndrome. 2. Gastrointestinal spasm secondary to organic diseases. **Dosage and Administration:** Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** *Tablets:* 0512/0044: *Suspension:* 0512/0061. Further information is available on request to the Company.

duphar Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

C/Hosp Ad/1/88

Why settle for 54% remis

PRESCRIBING INFORMATION: Dipentum
Presentation: Caramel coloured capsules containing 250mg olsalazine sodium. **Uses:** Oral treatment of acute mild ulcerative colitis and the maintenance of remission. Olsalazine consists of two molecules of 5-amino-salicyclic acid (5-ASA) joined through an azo-bond. The systemic absorption of olsalazine is minimal. 99% of an oral dose will reach the colon. Olsalazine is activated in the colon where it is converted into 5-ASA. The release of 5-ASA is neither pH nor time dependent. 5-ASA acts topically on the colonic mucosa and local colonic concentrations of 5-ASA are more than 1000 times that found in the serum. **Dosage and Administration:** ***Acute Mild Disease:*** *Adults including the Elderly.* Commence on 1g daily in divided doses and, depending upon the patient response, titrate the dose upwards to a maximum of 3g daily over 1 week. A single dose should not exceed 1g. Olsalazine should be taken with food. ***Remission:*** *Adults including the Elderly.* Two capsules (0.5g) twice daily taken with food. **Contra-indications: Warnings etc:** ***Contra-indications:*** Hypersensivity to salicylates. There is no experience of the use of olsalazine in patients with significant renal impairment. Olsalazine is contra-indicated in patients with significant renal impairment. ***Pregnancy:*** Reproduction studies performed in mice, rats and rabbits have revealed no evidence of impaired fertility, harm to the foetus or teratogenic effects due to olsalazine administration. However, the experience of use in pregnant women is limited. Dipentum should not be used during pregnancy unless the clinician considers that the potential benefit outweighs the possible risk to the foetus. ***Lactation:*** There are no data on the excretion of olsalazine in breast milk. **Adverse Reactions:** Watery diarrhoea has been recorded in 15% of patients treated. In half of these patients the diarrhoea was either transient or overcome by dose reduction. In patients who do not respond to dose reduction the drug should be stopped. As with sulphasalazine and mesalazine gastrointestinal side-effects are the most common. The most frequently reported adverse reactions are diarrhoea, abdominal cramps, headache, nausea, dyspepsia, arthralgia and rash. **Treatment of Overdose:** There is no specific antidote to olsalazine. Treatment should be supportive. **Pharmaceutical Precautions:** Store at room temperature in a dry place. **Legal Category:** POM. **Package Quantities:** Containers of 100 capsules. **Further Information:** Olsalazine has been used concomitantly with glucocorticosteroids. **Product Licence Number:** 0009 0069. **Product Licence Holder:** Pharmacia Biosystems Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. **Distributed by:** Kabi Pharmacia Ltd., Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. **References:**
1. Courtney, M.G. et al. (1992) The Lancet.; **339**: 1279-1281
2. Courtney, M.G. et al. (1990) The 9th World Congress of Gastroenterology, Sydney, Australia; Abstr. PP727.

Kabi Pharmacia

KV 1421 6 92

sion when you can achieve 76%?[1]

Ulcerative colitis can ruin lives with its distressing cycle of relapses. Surely the most rewarding strategy, once you've done the job of controlling the acute phase of this disease, is to maintain remission as effectively as possible.

A recent clinical study indicated a comfortable advantage for Dipentum over coated mesalazine in the maintenance of remission in ulcerative colitis.[2]
The findings of this study have been incorporated into a paper published in The Lancet[1], giving Dipentum 22% superiority in 12-month remission rates. But then what would you expect from a 5-ASA treatment that can deliver 99% of an oral dose to the colon?

IN ULCERATIVE COLITIS

Dipentum®
olsalazine sodium

Because remission means so much

DON'T BE BEHIND THE TIMES!

THE HEALTH DEBATE LIVE: 45 INTERVIEWS FOR *LEADING FOR HEALTH*



The BMA's document *Leading for Health: a BMA Agenda for Health*, encompasses often contrasting views and presents questions that need answering. What did people actually say in their interviews? With the interviewees permission, the BMJ has published the transcripts of their original comments. This collection provides a lively and provocative contribution to the health service debate.

ISBN 0 7279 0317 9 **192 pages**
Price: UK £10.95 ; Abroad £13.00 (BMA members £9.95 or £12.00)

THE FUTURE OF HEALTH CARE

The best way to provide health services is a subject that has to be tackled by governments and health professionals worldwide. The British government has been attempting this in its reforms of the NHS, and the BMA has produced its own "agenda for health". To give readers a better grasp of these issues the *BMJ* asked experts about the main topics on the agenda–such as rationing of care and funding of services–and to suggest action for the future.

ISBN 0 7279 0742 5 **104 pages**
Price: UK £8.95; Abroad £10.00 (BMA members £8.45 or £9.50)



AUDIT IN ACTION

From a minority interest to an integral part of good medical practice audit has come a long way. *Audit in Action* traces this development in a selection of articles originally published in the *BMJ*. The contributors are leaders in or experienced practitioners of audit. Covering audit both in hospitals and in general practice, this book is valuable reading for all those concerned to improve the quality of health care.

ISBN 0 7279 0317 9 **xiv + 246 pages**
Price: UK £10.95; Abroad £13.00; (BMA members: £9.95 or £12.00)



THE FUTURE OF GENERAL PRACTICE

General practitioners have recently had to cope with dramatic changes in their working conditions imposed on them by government policy. *The Future of General Practice* discusses what general practice should be and how it should be funded. The authors discuss topics at the heart of this debate, including research, audit, list sizes, fundholding, and general practitioners' educational needs.

ISBN 0 7279 0316 0 **116 pages**
Price: UK £7.95; Abroad £10.00; (BMA members: £7.45 or £9.50)

ORDER FORM British Medical Journal, PO Box 295, London WC1H 9TE

Please send me the following books:

Qty.	Title	Author/Editor	Amount
		Total	

Prices include postage, by air abroad

Name (print clearly) _____

Address _____

_____

_____ Postcode _____

☐ Please send me a book catalogue

Membership No. _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my American Express/Visa/Mastercard/Access

Card No. _____ Exp. date _____

Signature _____

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

VISIT *the* SPECIALIST MEDICAL BOOKSHOP



Located in London, the BMJ Bookshop offers a comprehensive range of medical titles, including a wide selection of student text books.

We offer an efficient mail order service and books are despatched post free in the UK. Any books in print will be obtained with the minimum of fuss.

Our helpful staff will provide you with accurate information as quickly as possible.

Come and browse in the relaxed atmosphere of the BMJ Bookshop.

BMJ Bookshop
Burton Street,
London WC1H 9JR
Tel: 071 383 6244 / 6638
Fax: 071 383 6662

Euston, Kings Cross, Russell Square



AMERICAN EXPRESS · Access · VISA

Open 9.30 am. to 5.00 pm. Monday to Friday



Guarding the Guardians: Research on

EDITORIAL PEER REVIEW

Following the success of the American Medical Association's First International Congress on Peer Review in Biomedical Publication, a second such Congress is being planned for September 1993. We aim to present original research on critical issues in the publication of all clinical and scientific research.

What are such critical issues?

- The mechanisms of peer review and editorial decision making in different journals
- The relationships between authors, editors, and reviewers, and how each is educated, selected, and evaluated.
- Allocation of responsibility for published material
- Quality assurance
- Breakdowns, weaknesses, and biases

For more information on attending or presenting research, contact:

Jane Smith, BA, MSc
Managing Editor, *BMJ*
BMA House
Tavistock Square
London WC1H 9JR
Telephone: 071-387-4499
Facsimile: 01-383-6418

AMA
AMERICAN MEDICAL ASSOCIATION

BEGIN PLANNING YOUR RESEARCH PROTOCOLS NOW!

ISSN 0399-8320

GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE

Gastroenterol Clin Biol, t. 16. N° 10 *October 1992*

CONTENTS

Subscriptions

Annual subscription — 10 issues/year
1992 : 233 US $
Please contact : S.P.P.I.F., B.P. 22 — F 41353 Vineuil (France)

A NEW FORCE IN PANCREATIC EXOCRINE INSUFFICIENCY





New **creon®** pancreatin 25000

Superior control of steatorrhoea†

† Compared with standard enteric-coated tablets in pancreatic insufficiency[1,2]

Prescribing Information

Presentation: Opaque orange/yellow hard gelatin capsules containing brownish coloured enteric coated pellets of pancreatin, equivalent to:
25,000 BP units of lipase
18,000 BP units of amylase
467 BP units of protease
Available in packs of 50. Basic NHS price £19.50

Indication: Pancreatic exocrine insufficiency.

Dosage and Administration: Adults (including elderly) and children: Initially one capsule with meals, then adjust according to response.
The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc. Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with very high doses of pancreatin.
Overdosage although not experienced until now, could precipitate meconium ileus equivalent. Perianal irritation, and rarely, inflammation, could occur when large doses are used.

Product Licence Number: 5727/0006

Name and Address of Licence Holder
Kali Chemie Pharma GmbH, Hans-Bockler-Allee 20, 3000, Hannover 1, Germany.

References
1. Stead R J et al. *Thorax* 1987; **42**: 533-37
2. Beverley D W et al. *Arch Dis Child* 1987; **62**: 564-68

Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281.
® Registered Trade Mark CRE/CP/JA/AUG 92

duphar
A member of the Solvay Group.